Author name: Claritas Rx

Introduction In the fast-paced world of biopharma, partnerships can drive remarkable advancements. GlaxoSmithKline (GSK), a global healthcare leader, is taking a bold step by teaming up with Flagship Pioneering, a trailblazer in venture creation and life sciences innovation. This collaboration aims to develop up to 10 new vaccines and pharmaceuticals, initially focusing on the respiratory […]

Introduction In the tough terrain of finding an Alzheimer’s cure, Eli Lilly is setting the pace with their latest innovation – the FDA-approved drug, Donanemab, commercially known as Kisunla. This blog delves into Lilly’s strategic maneuvers to expedite sales and cultivate urgent demand within the pharmaceutical sector. The vast population of patients combined with a

Within a sector populated by many market pioneers promoting injectable solutions, Pfizer is redefining the landscape with an oral medication for obesity. This article explores Pfizer‘s strategic moves towards securing a prominent position in the obesity treatment market, focusing especially on their groundbreaking work on a GLP-1 drug. Introduction Pfizer, a titan in the pharmaceutical

In the biopharma industry, understanding how your therapy basket’s fill rate stacks up against competitors can be a game-changer. This blog post dives deep into the significance of therapy basket fill rates, providing exclusive data insights and practical tips to help biopharma executives stay ahead in the competitive landscape. The Importance of Therapy Basket Fill

Picture a future in which we don’t merely manage symptoms but eliminate diseases at their roots. This future isn’t a far-off dream; it’s the promise of cell therapy. This innovative approach is currently changing the way we confront some of the toughest medical conditions. For biopharma investors, this arena doesn’t only symbolize a leap in

Mantle cell lymphoma (MCL) is a rare yet aggressive form of non-Hodgkin lymphoma, and treatment options have been limited for far too long. For pharmaceutical professionals and biopharma executives, staying at the forefront of treatment innovations is crucial. Recently, AstraZeneca has made significant strides with its BTK inhibitor, Calquence, challenging the current standard of care

The FDA unveiled a much-anticipated draft guide, outlining how businesses can secure approvals for platform technologies. This regulatory advance has the potential to fast-track the FDA’s ‘platform technology’ procedure, potentially accelerating the endorsement of cell and gene therapies. Keen to find out more? This comprehensive 15-page draft guide provides a wealth of knowledge for biopharma

AstraZeneca is experiencing tremendous success and progress under the leadership of CEO Pascal Soriot. His current objective is to achieve a revenue target of $80 billion by 2030. A decade ago, when AstraZeneca was experiencing a period of stagnation, the CEO projected a bold revenue goal of $45 billion by 2023. In a triumphant turn

The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering